科研速览 · Science Skim继续刷下去 · Keep skimming →
◆ Antimicrobial Agents and Chemotherapy2026-02-20· Chemistry

Optimizing target inactivation to treat multidrug-resistant <i>Escherichia coli</i> with NDM and PBP3 mutations: “going the extra mile”

Claudia Fabrizio, Felice Valzano, Simone Giuliano, Elisabetta Morelli, Daniela Serio, Giovanni Battista Buccoliero, Maurizio Cervellera, Gianfranco La Bella, Fabio Arena, Andrea M. Hujer, Magdalena A. Taracila, Steven Marshall, Robert A. Bonomo, Carlo Tascini

原始摘要(英文原文)· Original abstract
ABSTRACT A 65-year-old man without identifiable risk factors for multidrug-resistant pathogens was admitted with peritonitis, isolating NDM-producing Escherichia coli from a rectal swab and intraoperative samples. After surgery, ceftazidime-avibactam/aztreonam was administered. Due to poor clinical response, he was switched to imipenem-relebactam/aztreonam, resulting in a successful outcome. Whole-genome sequencing detected bla NDM-5 and bla CMY-148 β-lactamases, PBP3 YRIN insertion, and mutated cirA gene. This case illustrates the importance of considering different mechanisms of resistance when choosing combination therapy.
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Optimizing target inactivation to treat multidrug-resistant <i>Escherichia coli</i> with NDM and PBP3 mutations: “going the extra mile” — 科研速览 Science Skim